HIV Treatment in Dubai, Abu Dhabi & Sharjah

You Need Appointment for Service
Amet minim mollit non deserunt est sit aliqua la doremin
sidebar-1

Doctor-Led Antiretroviral Therapy, Medication Management & Ongoing HIV Care in the UAE

HIV treatment uses antiretroviral therapy (ART) to suppress the virus, preserve immune function, prevent HIV-related illness and—when viral suppression is maintained—prevent sexual transmission. Most people diagnosed with HIV should begin effective ART as soon as possible, with a regimen selected for their medical history, previous HIV prevention medicines, resistance risk, other conditions and potential interactions.

STDtest.clinic provides a pathway for confidential HIV-related assessment, treatment planning, prescription and medication coordination, laboratory monitoring and eligible home or hotel visits. Services involving HIV prescribing, dispensing or home administration are provided only within the applicable licensed clinical and pharmacy scope. A patient’s care may involve an HIV specialist or referral to an authorized treatment centre; the exact pathway is confirmed during assessment.

Starting HIV treatment after a confirmed diagnosis

A confirmed HIV diagnosis should lead to prompt linkage to care, not a prolonged wait for symptoms. ART is recommended for all people with HIV regardless of their initial CD4 count. NIH guidance supports immediate or rapid initiation for most people after diagnosis; many baseline samples can be collected before treatment while results are reviewed afterward. Particular opportunistic infections, such as cryptococcal meningitis or tuberculous meningitis, can require specialist decisions about ART timing.

A reactive screening test is not enough on its own to diagnose HIV. An initial reactive antigen/antibody test requires the appropriate confirmatory algorithm, which may include an HIV-1/HIV-2 differentiation assay and HIV RNA testing. Patients with discordant results need additional assessment before an ongoing HIV treatment label is applied.

The first consultation establishes both immediate safety and long-term treatment needs. A clinician reviews symptoms, previous tests, prior ART or PrEP/PEP exposure, current prescriptions and supplements, allergies, pregnancy potential, tuberculosis or hepatitis history, kidney and liver disease, cardiovascular risks, mental health and likely barriers to taking medicine consistently.

Baseline investigations usually include HIV RNA viral load, CD4 count, resistance testing, blood count, kidney and liver function, hepatitis A/B/C status and appropriate STI screening. Other tests, such as glucose, lipids, pregnancy testing, TB screening and HLA-B*5701 if abacavir is considered, depend on clinical circumstances. Most laboratory results should not unnecessarily delay an appropriate rapid-start regimen, but the clinician must select medicines safe while key results are pending.

How antiretroviral medicines control HIV

ART combines drugs that interrupt different steps of the HIV life cycle. Integrase strand transfer inhibitors (INSTIs) prevent integration of viral DNA into human cells; nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) interrupt viral DNA production. Other classes include protease inhibitors, non-nucleoside reverse transcriptase inhibitors, entry inhibitors and capsid inhibitors for particular situations.

Effective ART lowers the HIV viral load, often to undetectable levels within months. Time to suppression varies with initial viral load, adherence, regimen, resistance and health factors. A single dose does not make a person undetectable, and a low CD4 count is not itself a reason to withhold treatment.

ART controls HIV but does not ordinarily cure it. HIV can persist in long-lived cellular reservoirs even when routine blood tests cannot detect circulating virus. Stopping therapy can lead to viral rebound, immune injury and renewed transmission risk.

HIV treatment medicines, formulations and brand examples

The correct HIV medication is a complete regimen—not whichever tablet name appears in a search result. The following are guideline-based treatment examples. Brand examples describe products in relevant markets; they do not establish current UAE registration, STDtest.clinic stock, home delivery eligibility or an individual prescription.

Biktarvy: bictegravir / emtricitabine / tenofovir alafenamide

Biktarvy contains bictegravir 50 mg + emtricitabine 200 mg + tenofovir alafenamide 25 mg (BIC/FTC/TAF) in a fixed-dose tablet. It is an established complete HIV-1 treatment regimen for appropriate patients. Its components combine an integrase inhibitor with two NRTIs. A clinician checks kidney function, hepatitis B status, drug interactions and prior treatment/resistance history before prescribing. Antacids and mineral supplements containing certain cations can affect bictegravir absorption depending on timing and formulation.

Tivicay and dolutegravir-based combinations

Dolutegravir (DTG; Tivicay is a brand example) is an integrase inhibitor commonly used with two NRTIs. A typical initial combination is dolutegravir with tenofovir alafenamide or tenofovir disoproxil fumarate, plus emtricitabine or lamivudine. The exact strengths and tablet count depend on the products selected; dolutegravir should not be mistaken for complete HIV therapy when prescribed alone.

Tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), emtricitabine (FTC) and lamivudine (3TC) are active ingredients—not interchangeable brand labels. TDF/FTC is often formulated as 300 mg/200 mg, and TAF/FTC as 25 mg/200 mg in commonly used combinations. TDF may require closer renal and bone evaluation; TAF may affect weight or lipid parameters in some patients. Drug choice should also account for hepatitis B coinfection.

Dovato: dolutegravir / lamivudine

Dovato contains dolutegravir 50 mg + lamivudine 300 mg (DTG/3TC). NIH’s September 2026 guidance lists this two-drug combination among recommended initial regimens for selected people, but not when chronic hepatitis B is present or its status is unknown, when relevant resistance information is unavailable, or when rapid ART initiation is planned. It is not a substitute for a three-drug regimen when those conditions have not been assessed.

Triumeq and abacavir considerations

Triumeq contains dolutegravir 50 mg + abacavir 600 mg + lamivudine 300 mg. Abacavir can cause serious hypersensitivity in people carrying the HLA-B*5701 allele; testing is required before use. Cardiovascular risk and hepatitis B coinfection can also influence whether this option is appropriate. It is not a default choice for every new diagnosis.

Injectable HIV treatment and advanced regimens

Long-acting injectable ART may be an option for selected patients, but it is not the same as injectable PrEP. Cabotegravir plus rilpivirine (Cabenuva is a brand example) is a maintenance regimen for appropriately selected people with viral suppression and no relevant resistance or treatment-failure history. It requires a structured injection schedule, medication-interaction review and a plan for missed injections. Not every newly diagnosed person is eligible to start with this approach.

Other specialist regimens may be needed when drug resistance, prior treatment failure or intolerance limits standard options. Boosted darunavir-based regimens and newer agents may be considered under specialist guidance. The 2026 US approval of bictegravir/lenacapavir (Bixlenvo) does not itself confirm suitability or availability in the UAE. Lenacapavir used for PrEP and products used for HIV treatment must not be conflated.

Treatment selection for hepatitis B, kidney disease and other conditions

HIV and hepatitis B coinfection require a regimen that treats both viruses appropriately. In many patients, this means TAF or TDF combined with FTC or 3TC as part of full ART. Lamivudine alone is not sufficient hepatitis B treatment in coinfection, and stopping hepatitis B-active agents can cause serious hepatitis flares.

Reduced kidney function can change the preferred drug and dose. TDF, TAF and other agents have different renal considerations, while some fixed-dose products have eligibility thresholds. A clinician reviews estimated renal function, urine findings and other nephrotoxic medicines rather than automatically avoiding every tenofovir formulation.

Tuberculosis medicines, antacids, anticonvulsants and herbal supplements can interfere with HIV treatment. Rifampicin, for example, may require specific regimen adjustments. Calcium, iron and magnesium products can affect some integrase inhibitors. Patients should disclose all prescribed, over-the-counter and supplement products.

Pregnancy and plans to conceive require treatment, not treatment avoidance. ART protects maternal health and, when appropriately managed, substantially reduces perinatal transmission risk. Pregnancy-specific guidelines determine regimen choice, viral-load monitoring and delivery/newborn planning. Patients should not stop ART after a positive pregnancy test without immediate specialist advice.

Viral load, CD4 count and monitoring results

HIV viral load measures the amount of HIV RNA in blood and is the principal test for assessing whether treatment is suppressing the virus. A falling viral load is expected after effective ART. The clinician checks the result at appropriate intervals after initiation or changes, then periodically once suppression is stable.

CD4 count measures immune-system status rather than the quantity of virus. It helps assess immune recovery and the need for preventive treatment against certain opportunistic infections. A low CD4 count does not mean ART will fail, and a normal CD4 count does not mean HIV is cured.

An undetectable viral load depends on the assay’s reporting limit. It does not mean HIV has disappeared from the body. For sexual transmission counselling, sustained suppression to below 200 HIV RNA copies/mL is the evidence-based threshold used in U=U guidance, even if a particular laboratory reports a lower detection cutoff.

U=U means that a person with HIV who achieves and maintains viral suppression does not transmit HIV through sex. It is supported by substantial clinical evidence. Patients need continued ART and viral-load follow-up; U=U does not prevent other STIs or substitute for pregnancy prevention.

A detectable viral load after treatment requires context. A small isolated increase can be a transient ‘blip’; repeated or substantial viraemia warrants review of adherence, interactions, pharmacy interruptions, tolerability and resistance. The clinician should not automatically switch medicines based on one low-level result.

Side effects, missed doses and medication safety

Most modern ART regimens are well tolerated, but side effects and interactions are possible. Early nausea, headache or sleep changes may improve; some medicines affect kidney function, liver tests, weight, lipids or bone health. Severe rash, breathing difficulty, jaundice or other serious symptoms require urgent medical evaluation.

A missed dose should be managed according to the exact medicine’s product instructions and clinical advice. Patients should not double doses automatically, stop a complete regimen or substitute another person’s tablets. The care team can discuss reminders, travel supplies, insurance continuity and medicine-access plans.

Running out of ART is a clinical priority. Interruptions can cause viral rebound and, in some circumstances, resistance. Patients travelling between Dubai, Abu Dhabi, Sharjah and other locations should arrange adequate legal medication supply and documentation in advance.

Resistance testing can guide initial therapy and treatment changes. Prior use of long-acting cabotegravir PrEP, previous ART or certain PEP regimens can influence which resistance genes are tested and whether an integrase-based regimen is suitable while results are pending.

HIV symptoms, advanced disease and opportunistic infections

HIV symptoms cannot establish the diagnosis or determine whether treatment is working. Fever, rash, weight loss, oral thrush, night sweats and enlarged lymph nodes have many causes. HIV diagnosis requires an appropriate test algorithm; treatment response is measured with viral load and clinical assessment.

A person with a low CD4 count may need prevention or treatment for opportunistic infections in addition to ART. The choice depends on the CD4 threshold, prior infections, laboratory findings and symptoms. Some severe infections require hospitalization and specialist decisions about when to start or modify ART.

Urgent assessment is necessary for severe headache with fever or neck stiffness, breathing difficulty, confusion, visual changes, profound weakness or serious dehydration. These symptoms cannot be safely managed through a routine hotel or home appointment alone.

HIV treatment at home or in a hotel

Selected parts of ongoing HIV care may be delivered through licensed home-healthcare services. A clinician may review symptoms and adherence, reconcile medications, assess adverse effects, arrange suitable blood samples, coordinate repeat prescriptions and provide follow-up counselling when the patient’s condition is stable.

Medication dispensing or delivery is possible only when the exact product, prescription and applicable pharmacy permissions allow it. STDtest.clinic reports holding DHA, MOHAP and drug-sale permissions; the public site must connect those permissions to the specific legal entity, dispensing activity and emirate before promising home delivery of any named HIV medicine.

Not every HIV medicine is administered at home. Long-acting injectable ART requires an authorized setting, trained personnel, scheduled monitoring and management of adverse reactions. Hospital treatment, complex opportunistic infection management and specialist investigations cannot be replaced by a home visit.

A home blood draw does not automatically mean the entire HIV treatment service is licensed at that location. Patients should receive a clear explanation of which steps are provided by STDtest.clinic, which laboratory processes the sample and which HIV specialist or facility manages the prescription.

HIV care in Dubai, Abu Dhabi, Sharjah and the UAE

STDtest.clinic’s stated primary location is Arjan, Dubai. Dubai requests may arise from Palm Jumeirah, Dubai Marina, JBR, JLT, Downtown Dubai, Business Bay, DIFC, Dubai Hills Estate, Emirates Hills, Jumeirah, Al Barsha, Arabian Ranches, Bluewaters and Dubai Creek Harbour. These are relevant patient locations, not guaranteed mobile-service coverage.

Patients in Abu Dhabi may request care coordination from Saadiyat Island, Al Reem Island, Al Maryah Island, Yas Island, Al Raha Beach, Khalifa City, Al Bateen or the Corniche. Sharjah requests may include Al Majaz, Al Khan, Al Taawun, Muwaileh and Aljada. Whether a licensed home clinician, sample collector, prescription or medication delivery can be provided must be confirmed separately for each emirate and service.

People elsewhere in the UAE can enquire about consultation, authorized referral and continuity-of-care options. One emirate’s professional or facility licence does not automatically establish nationwide permission to prescribe, dispense or perform home visits.

Confidentiality, HIV status and UAE clinical requirements

HIV-related medical information should be handled with discretion, informed consent and appropriate access controls. Patients can ask how identification is verified, where records are stored, how results are communicated and which legal reporting duties apply.

Confidential care should not be advertised as fully anonymous or exempt from mandatory reporting. Immigration, residency, employment and insurance questions are governed by current UAE law and individual circumstances. Medical content should not promise particular legal outcomes without verified legal review.

A patient may need referral to an authorized HIV treatment centre even if a home assessment is available. The website should identify the verified treating entity, doctor credentials, laboratory arrangements, referral relationships and privacy policy rather than implying every part of specialist HIV care happens under one roof.

HIV treatment, PrEP and PEP are different clinical pathways

HIV treatment is prescribed after confirmed infection and usually continues long term. It aims to achieve and maintain viral suppression using a complete treatment regimen.

PrEP is taken by an HIV-negative person before possible exposures. Daily oral or eligible injectable regimens reduce the risk of acquiring HIV, but a person with suspected acute infection needs diagnostic assessment before PrEP is initiated.

PEP is emergency prevention after a potentially significant exposure. It should be assessed as soon as possible, ideally within 24 hours and no later than 72 hours, and generally involves 28 days of antiretroviral medicine. A person with a confirmed new HIV diagnosis needs full ART, not a PEP course.

An HIV medicine can appear in more than one prevention or treatment guideline without making the indications interchangeable. BIC/FTC/TAF, for example, is a complete HIV treatment regimen and may also be recommended in particular PEP protocols, but the clinical assessment and duration differ.

Living well with HIV and protecting partners

People receiving effective ART can live long, active lives. Outcomes improve with early treatment, regular viral-load monitoring, vaccinations, age-appropriate cancer screening, cardiovascular risk management, mental health support and treatment of other infections.

Condoms and routine STI testing remain useful even when HIV is undetectable. U=U concerns sexual HIV transmission; it does not prevent syphilis, gonorrhea, chlamydia or other infections. Partners without HIV may consider PrEP based on their own exposure pattern and preferences.

HIV treatment can support healthy relationships, family planning and pregnancy. Decisions about conception, pregnancy and infant care should be made with an experienced clinical team using current perinatal guidance.

How STDtest.clinic coordinates HIV treatment

The first step is a confidential clinical review of the diagnosis and existing treatment. Patients can provide prior HIV tests, viral-load and CD4 results, a medication list, past resistance reports and relevant medical history.

The clinician then determines the safest care pathway. This may include confirming HIV status, arranging baseline investigations, discussing prompt ART initiation, reconciling an existing regimen or referring to an authorized specialist.

Before medication is promised, the exact formulation and supply route are checked. The team should verify prescription authority, medicine registration, pharmacy stock, dispensing permissions, price and whether any home delivery or administration is allowed.

Follow-up is planned around measurable results. The care team reviews viral load, adherence, side effects, interactions, immunization needs and other health risks, and coordinates specialist care when required.

Medical notice and clinical sources

HIV medicines should not be started, stopped, exchanged or shared without qualified medical guidance. This page is for patient education and service navigation; it is not an individual prescription. Actual products, UAE availability, laboratory partners, fees, doctor licensing and emirate-specific home services require confirmation before booking.

Scroll to Top